Yeung-Chul Mun

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3296920/publications.pdf

Version: 2024-02-01

119	1,126	394421	454955
papers	citations	19 h-index	30 g-index

121	121	121	2214
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica, 2016, 101, 717-723.	3.5	129
2	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 2013, 161, 339-347.	2.5	72
3	Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 7180-7188.	7.0	57
4	Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines. Journal of Korean Medical Science, 2014, 29, 164.	2.5	55
5	Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2007, 82, 1-5.	4.1	51
6	Acute Fibrinous and Organizing Pneumonia Following Hematopoietic Stem Cell Transplantation. Korean Journal of Internal Medicine, 2009, 24, 156.	1.7	43
7	Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia. Acta Haematologica, 2007, 118, 205-208.	1.4	37
8	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. American Journal of Hematology, 2017, 92, 1280-1286.	4.1	34
9	VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Science, 2012, 103, 497-503.	3.9	33
10	Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Arrayâ€“Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype. Journal of Clinical Oncology, 2011, 29, 4702-4708.	1.6	30
11	Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leukemia and Lymphoma, 2016, 57, 341-347.	1.3	30
12	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. The Lancet Regional Health - Western Pacific, 2021, 10, 100126.	2.9	30
13	Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. Experimental and Molecular Medicine, 2005, 37, 45-50.	7.7	29
14	Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. Journal of Clinical Virology, 2015, 73, 64-69.	3.1	25
15	Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease. Korean Journal of Internal Medicine, 2014, 29, 445.	1.7	24
16	Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional Dyspepsia. Journal of Neurogastroenterology and Motility, 2019, 25, 212-221.	2.4	24
17	Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Annals of Hematology, 2016, 95, 337-344.	1.8	22
18	Longâ€term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). British Journal of Haematology, 2020, 189, 303-312.	2.5	21

#	Article	IF	Citations
19	Management of immune thrombocytopenia: Korean experts recommendation in 2017. Blood Research, 2017, 52, 254.	1.3	20
20	Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Annals of Hematology, 2013, 92, 459-469.	1.8	19
21	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Annals of Hematology, 2014, 93, 1353-1361.	1.8	18
22	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget, 2015, 6, 44985-44994.	1.8	17
23	Weekly rituximab consolidation following four cycles of Râ€<scp>CHOP</scp> induction chemotherapy in very elderly patients with diffuse large Bâ€cell lymphoma: Consortium for improving survival of lymphoma study (<scp>CISL</scp>). European Journal of Haematology, 2015, 94, 504-510.	2.2	16
24	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget, 2017, 8, 79517-79526.	1.8	16
25	Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach. The Korean Journal of Hematology, 2010, 45, 171.	0.7	15
26	Clinical features and treatment outcome of primary systemic lightâ€chain amyloidosis in Korea: Results of multicenter analysis. American Journal of Hematology, 2013, 88, 52-55.	4.1	14
27	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget, 2016, 7, 72033-72043.	1.8	14
28	Prognostic Significance of CD44s Expression in Biliary Tract Cancers. Annals of Surgical Oncology, 2008, 15, 1155-1160.	1.5	12
29	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 92171-92182.	1.8	12
30	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. Cancer Research and Treatment, 2015, 47, 173-181.	3.0	10
31	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. Blood Cancer Journal, 2021, 11, 190.	6.2	10
32	Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. Blood Research, 2022, 57, 20-28.	1.3	10
33	Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial. Blood, 2015, 126, 476-476.	1.4	9
34	Gene expression profile related to prognosis of acute myeloid leukemia. Oncology Reports, 0, , .	2.6	8
35	A genomeâ€wide singleâ€nucleotide polymorphismâ€array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. American Journal of Hematology, 2012, 87, 961-968.	4.1	8
36	Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. International Journal of Hematology, 2012, 96, 327-333.	1.6	8

#	Article	IF	Citations
37	A proposal for improvement in the utilization rate of banked cord blood. Blood Research, 2013, 48, 5.	1.3	8
38	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Annals of Hematology, 2020, 99, 1283-1291.	1.8	8
39	Suppressive effect of Î±-mangostin for cancer stem cells in colorectal cancer via the Notch pathway. BMC Cancer, 2022, 22, 341.	2.6	8
40	Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study. Blood, 2018, 132, 4252-4252.	1.4	7
41	Genomeâ€wide genotypeâ€based risk model for survival in acute myeloid leukaemia patients with normal karyotype. British Journal of Haematology, 2013, 163, 62-71.	2.5	6
42	Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH Rearrangements. Annals of Laboratory Medicine, 2015, 35, 128-131.	2.5	6
43	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS ONE, 2016, 11, e0166245.	2.5	6
44	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. Blood, 2011, 118, 1517-1517.	1.4	6
45	Single Nucleotide Polymorphism Array-Based Karyotyping in Acute Myeloid Leukemia or Myelodysplastic Syndrome with Trisomy 8 as the Sole Chromosomal Abnormality. Acta Haematologica, 2013, 129, 154-158.	1.4	5
46	Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia. Cancer Genetics, 2015, 208, 630-635.	0.4	5
47	Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). Journal of Korean Medical Science, 2018, 33, e142.	2.5	5
48	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 656-664.	0.4	5
49	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. Cancer Research and Treatment, 2021, , .	3.0	5
50	Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study. Osteoporosis International, 2022, 33, 367-377.	3.1	5
51	Topoisomerase II Alpha and Microtubule-associated Protein-tau as a Predictive Marker in Axillary Lymph Node Positive Breast Cancer. Tumori, 2014, 100, 80-86.	1.1	5
52	Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma. Cancer Research and Treatment, 2005, 37, 370.	3.0	4
53	Additional Genomic Aberrations Identified by Single Nucleotide Polymorphism Array-Based Karyotyping in an Acute Myeloid Leukemia Case with Isolated del(20q) Abnormality. Annals of Laboratory Medicine, 2012, 32, 445-449.	2.5	4
54	Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia. Hematology, 2021, 26, 904-913.	1.5	4

#	Article	IF	Citations
55	Ring Chromosome 5 in Acute Myeloid Leukemia Defined by Whole-genome Single Nucleotide Polymorphism Array. Annals of Laboratory Medicine, 2012, 32, 307-311.	2.5	3
56	Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. Annals of Hematology, 2018, 97, 955-965.	1.8	3
57	GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of Laboratory Medicine, 2018, 38, 296-305.	2.5	3
58	Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species. Molecules and Cells, 2020, 43, 813-820.	2.6	3
59	The Differences in Resting Pulmonary Function in Relation to the Nutritional status of Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2001, 51, 570.	0.2	2
60	A Case of Coexistent Chronic Lymphocytic Leukemia and Multiple Myeloma. The Korean Journal of Hematology, 2005, 40, 41.	0.7	2
61	Transplant physicians' perceptions of cord blood transplantation in Korea: a questionnaire survey. Blood Research, 2014, 49, 228.	1.3	2
62	ETV6/RUNX1 Rearrangement Identified by RT-PCR without Evidence on FISH. Acta Haematologica, 2014, 132, 122-124.	1.4	2
63	Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. Annals of Hematology, 2019, 98, 2273-2281.	1.8	2
64	Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS). Blood, 2019, 134, 1643-1643.	1.4	2
65	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean Journal of Internal Medicine, 2015, 30, 675-683.	1.7	2
66	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Medical Journal, 2020, 61, 452.	2.2	2
67	Relative Risk for Lung Cancer According to Smoking Habits in Korean. Tuberculosis and Respiratory Diseases, 2000, 48, 331.	0.2	1
68	The Results of Danazol Therapy in Patients with Chronic Immune Thrombocytopenic Purpura Who Failed with Corticosteroid Therapy. The Korean Journal of Hematology, 2007, 42, 353.	0.7	1
69	Two Cases of Medical Device-RelatedCorynebacterium striatumInfection: A Meningitis and A Sepsis. Annals of Clinical Microbiology, 2016, 19, 28.	0.1	1
70	Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. Annals of Laboratory Medicine, 2018, 38, 160-164.	2.5	1
71	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. Supportive Care in Cancer, 2021, 29, 4969-4977.	2.2	1
72	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. International Journal of Hematology, 2021, 114, 355-362.	1.6	1

#	Article	IF	Citations
73	The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study. Blood, 2018, 132, 4853-4853.	1.4	1
74	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. Blood, 2008, 112, 5184-5184.	1.4	1
75	The Influence of Fat-Free Mass to Maximum Exercise Performance in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2002, 52, 346.	0.2	1
76	Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study. Blood, 2020, 136, 51-52.	1.4	1
77	Diagnostic Value of Cyfra 21-1 in Differential Diagnosis of Pleural Effusion. Tuberculosis and Respiratory Diseases, 1999, 47, 50.	0.2	0
78	The Differences of the Smoking Habit Between Emphysema and Chronic Bronchitis. Tuberculosis and Respiratory Diseases, 2001, 50, 693.	0.2	0
79	Vascular Complications in Patients with Essential Thrombocythemia. The Korean Journal of Hematology, 2006, 41, 149.	0.7	0
80	Effects of Transmigration of Bone Marrow Nuclear Cells Through Endothelial Cell and Stromal Cell by Leukotriene B4and Inhibition of Reactive Oxygen Species. Ewha Medical Journal, 2008, 31, 65.	0.0	0
81	Sole Trisomy 22 Not Associated with inv(16) in Myelodysplastic Syndrome. The Ewha Medical Journal, 2012, 35, 62.	0.2	0
82	Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S16.	0.4	0
83	Characteristics of Chromosome 17p Aberrations Identified by Metaphase Cytogenetics, Interphase FISH and Sequencing in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e37.	0.4	0
84	Neutrophilic Leukemoid Reaction Associated with Malignancy Initially Suspected as Chronic Neutrophilic Leukemia. Laboratory Medicine Online, 2017, 7, 206.	0.2	0
85	Anaplastic Large Cell Lymphoma with Massive Eosinophilia and Complex Karyotype Initially Misdiagnosed as Chronic Eosinophilic Leukemia. Laboratory Medicine Online, 2018, 8, 56.	0.2	0
86	A Case of Combined Small Cell Carcinoma with Non-Small Cell Lung Carcinoma, Adenocarcinoma and Squamous Cell Carcinoma. Tuberculosis and Respiratory Diseases, 2000, 48, 72.	0.2	0
87	Effect of Neutrophil Elastase inhibitor, ICI 200,355, on Interleukin-1 Induced acute lung injury in rats. Yeungnam University Journal of Medicine, 2002, 19, 55.	0.1	0
88	Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study. Cancer Research and Treatment, 2003, 35, 213-217.	3.0	0
89	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 3288-3288.	1.4	0
90	The LTB4 Receptor Is Involved Not Only in the Downstream Pathway of rh-GCSF Mobilization but in the LTB4 Mobilization Pathway in C57BL/6 Mice.. Blood, 2006, 108, 5216-5216.	1.4	0

#	Article	IF	Citations
91	The Intention To Treat Analysis of the Different Post Remission Therapy Modalities in AML Patients with the â€œIntermediate Risk Group (IPG)â€•Based on Cytogenetics.. Blood, 2006, 108, 4563-4563.	1.4	0
92	Augmented Effects on Neovascularization by Mixing the Conditioned Medium from Early EPCs into Late EPCs Derived from Human Cord Blood.. Blood, 2006, 108, 3936-3936.	1.4	0
93	VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 994-994.	1.4	0
94	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. Blood, 2011, 118, 1990-1990.	1.4	0
95	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.. Blood, 2012, 120, 2683-2683.	1.4	0
96	Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. Blood, 2013, 122, 5379-5379.	1.4	0
97	Chromothripsis Identified by Copy Number Profiling in a Case of Plasma Cell Leukaemia. Journal of Laboratory Medicine and Quality Assurance, 2014, 36, 107-112.	0.4	0
98	Systemic Epstein-Barr Virus-Positive T-cell Lymphoproliferative Disease of Childhood Presenting as Hemophagocytic Lymphohistiocytosis with Chromosomal Abnormalities. Journal of Laboratory Medicine and Quality Assurance, 2014, 36, 210-215.	0.4	0
99	Therapeutic Plasma Exchange for a Patient with Severe Cold Agglutinin Disease. The Korean Journal of Blood Transfusion, 2015, 26, 75-80.	0.4	0
100	Manipulation of Î²-catenin pathway to overcome endocrine resistance in breast cancer.. Journal of Clinical Oncology, 2015, 33, e11530-e11530.	1.6	0
101	Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib. Blood, 2015, 126, 4053-4053.	1.4	0
102	Abstract B49: Inhibition of Î²-catenin pathway to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. , 2015, , .		0
103	Prognostic Impact of Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. Blood, 2016, 128, 5432-5432.	1.4	0
104	Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation. Blood, 2016, 128, 3375-3375.	1.4	0
105	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). Blood, 2016, 128, 4445-4445.	1.4	0
106	Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study. Blood, 2016, 128, 1920-1920.	1.4	0
107	Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL). Blood, 2016, 128, 3466-3466.	1.4	0
108	Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5683-5683.	1.4	0

#	Article	IF	Citations
109	Lymphedema Associated With Primary Amyloidosis: A Case Study. Annals of Rehabilitation Medicine, 2017, 41, 887.	1.6	0
110	Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. Laboratory Medicine Online, 2018, 8, 41.	0.2	0
111	Inhibition of Autophagy with 3-Methyladenine Potentiates Bortezomib-Induced Apoptosis of Myeloma Cell Via up Regulation of Mitochondrial Reactive Oxygen Species. Blood, 2018, 132, 4472-4472.	1.4	0
112	Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors. Blood, 2018, 132, 3017-3017.	1.4	0
113	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. Blood, 2018, 132, 3876-3876.	1.4	0
114	Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up. Blood, 2018, 132, 1733-1733.	1.4	0
115	Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Blood, 2019, 134, 3114-3114.	1.4	0
116	Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study. Blood, 2019, 134, 4035-4035.	1.4	0
117	Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCR. Laboratory Medicine Online, 2020, 10, 321-325.	0.2	0
118	Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT. Blood, 2021, 138, 3757-3757.	1.4	0
119	Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease. Blood, 2021, 138, 2889-2889.	1.4	0